Facing record-high volatility and market uncertainty, one biotech is scheduled for the week ahead.
Formed by New Enterprise Associate’s orphan drug accelerator Cydan, genetic disorder biotech Imara (IMRA) plans to raise $76 million at a $301 million market cap. The Boston-based company’s sole candidate IMR-687 is a once-a-day therapy targeting sickle cell disease and beta-thalassemia by inhibiting PDE9. It is expected to begin a Phase 2b trial in the 1H20. While there is significant unmet medical need for both disorders, it is a crowded space, with three products approved in 2019.
{iframe}https://seekingalpha.com/article/4330459-u-s-ipo-week-ahead-one-biotech-takes-on-turbulent-ipo-market{/iframe}